-
Hengrui’s Long-Acting Insulin Analogue Accepted for Review by China’s NMPA
•
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that its market filing for a long-acting insulin analogue, a Category 1 biologic product, has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone for Hengrui as it seeks to bring China’s first…
-
AbbVie Partners with Neomorph on Molecular Glue Degraders for Oncology and Immunology
•
US-based pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with Neomorph, Inc., aimed at developing novel molecular glue degraders for multiple targets across oncology and immunology. The partnership seeks to leverage Neomorph’s innovative technology to address critical needs in cancer and immune-related diseases. Molecular Glue…
-
Sino Medical Sciences Wins Peru Approval for Coronary Balloon Catheter
•
China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving marketing approval from Peru’s Dirección General de Medicamentos, Insumos y Drogas (DIGEMID) for its SC HONKYTONK coronary balloon dilation catheter. This marks another milestone in the global expansion of the company’s product portfolio, further solidifying its presence in international…
-
Shenzhen Beike Initiates First Chinese Stem Cell Study for Systemic Lupus Erythematosus
•
China-based stem cell specialist Shenzhen Beike Biotechnology Co., Ltd has announced the initiation of a Phase I/II clinical study for human umbilical cord mesenchymal stem cells in patients with moderate to severe systemic lupus erythematosus (SLE). This marks the first regulatory study for stem cell therapy targeting SLE in China,…
-
Accuray’s Tomo C System Completes Treatment of First 100 Patients in China
•
US-based medical device firm Accuray Inc. (NASDAQ: ARAY) has announced the completion of treating the first 100 patients using its Tomo C Radiation Treatment Delivery System at the Shandong Cancer Hospital and Institute. The milestone marks a significant achievement for the Tomo C System, which was developed through the CNNC-Accuray…
-
Ascentage Pharma Prices US IPO at USD 17.25 per ADS
•
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) has announced the pricing of its initial public offering (IPO) of 7,325,000 American depositary shares (ADSs) in the United States at USD 17.25 per share, prior to underwriting discounts and commissions. The ADSs are scheduled to begin trading on the Nasdaq Global Market…
-
United Laboratories’ Biosimilar Semaglutide Accepted for Review by China’s NMPA
•
Hong Kong-listed United Laboratories International Holdings Ltd (HKG: 3933) has announced that its market filing for a biosimilar version of Novo Nordisk’s (NYSE: NVO) weight loss drug semaglutide (Ozempic/Wegovy) has been accepted for review by China’s National Medical Products Administration (NMPA). This marks a significant step towards introducing a more…
-
Beijing Aosaikang’s ASKB589 Shows Promise in Phase I/II Study for Gastric Cancer
•
China’s Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has unveiled the latest results from a Phase I/II study of its Category 1 biologic product candidate ASKB589, which is being evaluated as a first-line treatment for advanced gastric/esophagogastric junction (G/GEJ) adenocarcinoma. The study assessed the efficacy and safety of ASKB589 in…
-
Biogen’s Higher-Dose Spinraza Regimen Under Review by FDA and EMA
•
US-based biopharmaceutical company Biogen (NASDAQ: BIIB) has submitted supplemental New Drug Applications (sNDAs) to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for a higher-dose regimen of its spinal muscular atrophy (SMA) treatment, Spinraza (nusinersen). The applications are currently under review by both regulatory bodies,…
-
Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease
•
Denmark-based Novo Nordisk A/S (NYSE: NVO) has entered into a strategic collaboration and license agreement with US-headquartered IMMvention Therapeutix, Inc. to develop and commercialize oral therapies targeting the BACH1 pathway for sickle cell disease (SCD) and other chronic conditions. The partnership aims to leverage IMMvention’s expertise in BACH1 inhibition to…
-
Zai Lab’s ZL-1310 Granted Orphan Drug Designation by FDA for SCLC
•
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its ZL-1310, a potential first-in-class DLL3-targeted antibody drug conjugate (ADC) for the treatment of small cell lung cancer (SCLC). This designation underscores the drug’s…
-
Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies
•
Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has expanded its strategic partnership with Cambridge, Massachusetts-based Orna Therapeutics. The collaboration now includes BCMA (B-cell maturation antigen) as a designated biological target for RNA-based therapeutics development. This partnership aims to leverage Orna’s groundbreaking circular RNA (oRNA) technology…
-
Johnson & Johnson Reports Q4 Growth, Projects 2025 Sales Outlook
•
US-based Johnson & Johnson (J&J, NYSE: JNJ) has released its Q4 2024 financial results, reporting global sales of USD 22.52 billion, a robust 5.3% year-on-year (YOY) operational growth excluding currency fluctuations. Net profit for the quarter was USD 3.431 billion, down 17.0% YOY. For the full year, annual sales reached…
-
YolTech Initiates Study for YOLT-204 in Transfusion-Dependent Beta-Thalassemia
•
Shanghai-based YolTech Therapeutics, a biotech startup specializing in lipid nanoparticle delivery and gene editing, has announced the initiation of a dosage escalation study to preliminarily assess the safety and efficacy of a single-dose regimen with YOLT-204 in transfusion-dependent beta-thalassemia (TDT). This marks a significant step forward in the development of…
-
Haichang Bio’s siRNA Drug HC016 Cleared for US Clinical Trials
•
China-based Zhejiang Haichang Biotech Co., Ltd has announced that its siRNA drug, HC016 complex lipid, has been cleared by the US Food and Drug Administration (FDA) for clinical trials. This marks a significant milestone in the development of innovative treatments for solid tumors, leveraging Haichang Bio’s proprietary QTsome technology platform.…
-
iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies
•
Hangzhou-based cell therapy specialist iMBIORAY has reportedly raised close to RMB 100 million (USD 13.7 million) in a Series A+ financing round. The round was led by Sinowisdom, with contributions from Tailong VC, HY Capital, and other investors. The proceeds will be used to advance the clinical development of universal…
-
Abbott Labs Posts Q4 Growth, Projects Strong 2025 Outlook
•
US-based Abbott Laboratories (NYSE: ABT) has released its Q4 2024 financial results, reporting an 8.8% increase in organic sales to USD 10.974 billion. Excluding COVID-19 testing-related sales, the company achieved a 10.1% growth rate. For the full year, Abbott generated USD 42.0 billion in revenues, up 7.1% on an organic…
-
Shenzhen TargetRx Raises $50M in Series C Financing for Global Clinical Trials
•
China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, has announced the completion of a Series C financing round, raising USD 50 million. The funds will be used to advance overseas clinical studies for multiple innovative drugs, positioning the company for global expansion. Company Background and PipelineFounded in 2014,…
-
Haisco’s HSK44459 Approved for Clinical Trials in Behcet’s Disease
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for its investigational product HSK44459 in Behcet’s disease. This rare disease is listed in China’s second catalogue of rare diseases, highlighting the significant unmet medical need it represents. Behcet’s…
-
Fosun’s Plan to Take Henlius Private Fails After Shareholder Vote
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its plan to take its subsidiary Shanghai Henlius Biotech Inc. (HKG: 2696) private has fallen through after the shareholder vote did not pass in accordance with the terms. As a result, the listing of Henlius’ H Shares…
